Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APB R3

Next Previous
Drug Profile

APB R3

Alternative Names: APB-R3; EVO-301; Long-acting IL-18BP; Long-acting interleukin-18 binding protein

Latest Information Update: 15 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator APRILBIO
  • Developer APRILBIO; Evommune
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Hepatoprotectants; Proteins; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Interleukin-18 binding protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Ulcerative colitis
  • Preclinical Liver disorders
  • No development reported Adult-onset Still's disease

Most Recent Events

  • 07 May 2026 Evommune plans a phase IIb trial of EVO301 for Atopic dermatitis in mid-2027 (SC)
  • 07 May 2026 Evommune plans phase II trials in Ulcerative colitis, Cardiovascular disorders, and Food hypersensitivity
  • 28 Mar 2026 No recent reports of development identified for phase-I development in Adult-onset-Still's-disease(In volunteers) in Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top